- 中文名稱
Anti-Mouse CCL-9
- 英文名字
- Anti-Mouse CCL-9
- 供應商
- ReliaTech
- 產品貨號
- 103-M338
- 產品報價
- ¥詢價/100ug

- 產品說明書
- 點擊查看
- 購買方式
- 90%產品中國有現貨庫存。銀行轉賬、電匯、支票、現金,在線支付寶及網銀支付,或直接與我們電話聯系400-6800-868
- 產品新聞

- 背景資料
- Mouse CCL9/10 (also named MIP1γ and MRP2) is an 11 kDa, secreted, monomeric polypeptide that belongs to the β (or CC) intercrine family of chemokines. Based on its activity and amino acid (aa) sequence, it is further classified as a member of the NC6 or six cysteinecontaining CC subfamily of chemokines. This subfamily contains four Nterminally extended chemokines, two human (CCL15 and CCL23) and two mouse (CCL9 and CCL10). Within this subfamily, there are no humanto rodent interspecies orthologs. Mouse CCL9/10 is synthesized as a 122 aa precursor that contains a 21 aa signal sequence and a 101 aa mature region with six cysteines. As noted, the mature region has an expanded Nterminus relative to other CC family members, and it forms a third intrachain disulfide bond with its two extra cysteines. Mouse CCL9/10 is 75% aa identical to rat CCL9/10. Chemokines are known to undergo proteolytic processing to generate multiple isoforms. NC6 chemokines are usually only marginally active at fulllength, but are converted to highly active forms upon Nterminal truncation. Mature CCL9, in the presence of inflammatory fluids, is naturally truncated by 28, 29 or 30 aa at the Nterminus, generating a highly active, 8 kDa, 71 73 aa CCR1 ligand. In contrast, other CCR1 ligands, CCL3/MIP1α and CCL5/RANTES, lose their potency when proteolytically processed. CCL9/10 is constitutively secreted, and circulates as a fulllength molecule. Any onset of inflammation with subsequent enzyme release may act on local NC6 chemokines, generating early, potent leukocyte chemoattractants.
- 應用類型
- WB, N
- 免疫原
- 該Anti-Mouse CCL-9的詳細信息查看ReliaTech提供的產品說明書。
- 來源宿主
- 該Anti-Mouse CCL-9的詳細信息查看ReliaTech提供的產品說明書。
- 反應性
- 該Anti-Mouse CCL-9的詳細信息查看ReliaTech提供的產品說明書。
- 保存建議
- 該Anti-Mouse CCL-9的詳細信息查看ReliaTech提供的產品說明書。溶解建議:Centrifuge vial prior to opening. Reconstitute the antibody with 500 μl sterile PBS and the final concentration is 200 μg/ml.
- 其他
- ReliaTech全稱為受體配體技術有限公司 (Receptor Ligand Technologies GmbH),1999年成立,總部位于德國不倫瑞克,是一家后基因組生物技術公司。ReliaTech主要專注于受體和配體的發現與研究。此外,ReliaTech也開發應用于血管與淋巴管生成研究的相關高品質試劑。目前ReliaTech提供近2800款產品,產品線主要包括重組蛋白(細胞因子、生長因子、可溶性受體)、抗體、ELISA試劑盒等。

- 注意
-
該頁面的中文產品信息的翻譯,僅供參考。準確的產品信息請以廠家的英文說明書為準。下單前,請瀏覽說明書確認。
-